|
COPYRIGHT 2002 Adams Business Media
It's a good thing Greg Aurand possesses fistfuls of self-confidence. With its potential for unprecedented gains and death-defying drops, it takes guts to take on a stock sector like biotechnology. Aurand has mastered subduing biotech's risk and volatility since joining Orbitex Funds in September 2001.
As a portfolio manager on the Health and Biotechnology Fund and Medical Sciences Fund, Aurand has shown that he has the skill to back up his confidence. For the fourth quarter ending December 31, 2001, the Health and Biotechnology Fund and the Medical Sciences Fund returned 15.18% and 24.65%, respectively. Both funds significantly outperformed the Upper Health and Biotechnology Fund Index, which had an average return of 8.62%.
After graduating from Michigan State University Aurand started out as a fixed-income advisor and trader with regional firms in the Midwest. It hit him at an interesting time that fixed income wasn't where he belonged. "I was sitting in my CFA exam and I realized that a lot of questions were on equity research and fundamentals. While it covered the fixed income area, the heaviest focus was on equity research.
"I found myself drawn to that, because, while a bond is...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
